Navigation Links
AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
Date:12/3/2008

All amounts are in U.S. dollars

QUEBEC CITY, Dec. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, announces that it has completed the transaction under the previously announced purchase and sale agreement with Cowen Healthcare Royalty Partners, L.P. ("CHRP") relating to AEterna Zentaris' rights to royalties on future sales of Cetrotide(R) covered by its license agreement with Merck Serono. AEterna Zentaris received $52.5 million from CHRP at closing, less certain transaction costs. Under the terms of the agreement with CHRP, AEterna Zentaris would receive an additional payment of $2.5 million from CHRP contingent on 2010 net sales of Cetrotide(R) reaching a specified level.

About Cetrotide(R) (cetrorelix)

Cetrotide(R) (cetrorelix) was the first luteinizing hormone-releasing hormone (LHRH) antagonist treatment approved for in vitro fertilization. It is administered to women to prevent premature ovulation in order to increase fertility success rate. Developed in cooperation with Medicine Nobel-Prize winner, Professor Andrew Schally of Veterans Affairs, Miami, Florida, it was launched in Europe in 1999 and in the United States in 2001. Cetrotide(R) is currently marketed worldwide by Merck Serono, except for Japan where it is marketed by Nippon Kayaku and Shionogi.

Cetrorelix is also currently in a Phase 3 program in benign prostatic hyperplasia involving 1,500 patients in North America and Europe. First results are expected in Q3 2009 with an NDA filing to follow in 2010 and potential launch in 2011.

About Cowen Healthcare Royalty Partners

Cowen Healthcare Royalty Partners ("CHRP") is a global healthcare private equity firm with over $500 million in capital under management. The firm invests principally in commercial-stage biopharmaceutical and medical device companies and products, through the purchase of royalty or Synthetic Royalty(SM) interests, debt and equity. CHRP's investment team has over 90 years of healthcare related experience including principal investing, structured finance, healthcare industry senior management, Wall Street research and consulting, scientific and clinical experience. For more information, please visit www.cowenroyalty.com.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... Aditya Humad, Acting CFO of AxioMed and Managing Partner of KICVentures, is ... is now gaining interest from Silicon Valley. “It was satisfying to complete the due ... say that, “We expect interest to continue to rise as AxioMed completes its cleanroom ...
(Date:12/9/2016)... PUNE, India , December 9, 2016 ... Product & Services (Primer, Probe, Custom, Predesigned, Reagent Equipment), Application (Research, ... - Forecasts to 2021" published by MarketsandMarkets, the global market is ... Billion in 2016, at a CAGR of 10.6% during the forecast ... ...
(Date:12/8/2016)... Philadelphia, PA (PRWEB) , ... December 08, 2016 ... ... fan engagement platforms, the business of innovation is taking over sports. On Thursday, ... executive will explore how technology is disrupting the playing field at a Smart ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... light to control cells — optogenetics — is key to exciting advances in ... the art, spatially patterned light projected via free-space optics stimulates small, transparent organisms ...
Breaking Biology Technology:
(Date:11/22/2016)... November 22, 2016 According to the new market ... Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact ... MarketsandMarkets, the market is expected to grow from USD 10.74 Billion in ... 16.79% between 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... 17, 2016 Global Market Watch: Primarily ... Banks, Population-Based Banks and Academics) market is to witness a ... Biobanks shows the highest Compounded Annual Growth Rate (CAGR) of ... during the analysis period 2014-2020. North America ... followed by Europe at 9.56% respectively. ...
(Date:11/15/2016)... Research and Markets has announced the addition of the ... offering. ... The global bioinformatics market is ... Billion in 2016, growing at a CAGR of 21.1% during the ... driven by the growing demand for nucleic acid and protein sequencing, ...
Breaking Biology News(10 mins):